erlotinib Articles
Regulatory briefs from Ipsen/Inspiration, Janssen and Astellas
20 November 2012
India's Cipla cuts prices of three cancer drugs
12 November 2012
AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute
10 September 2012
75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch
21 June 2012
NICE recommends Roche's Tarceva for NSCLC
10 May 2012
UK NICE asks for more data on Tarceva, and Botox for migraine
17 February 2012
European oncologists indicate Tarceva will threaten market position of Iressa in mutated EGFR NSCLC
2 November 2011
Roche’s Tarceva Oked in EU for first-line use in a genetically distinct type of lung cancer
2 September 2011
Europe’s CHMP adopts positive opinions on Dexdor, Incivo, Plenadren, Vyndaqel and Zytiga; backs extensions
23 July 2011
More negative opinions on cancer drugs from UK’s NICE
11 March 2011
Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint
31 January 2011
UK’s NICE not to recommend Roche’s Tarceva for NSCLC and Novartis’ Afinitor rejected for kidney cancer, with both drugmakers to appeal
26 November 2010
Pfizer calls a halt to Phase III study of Sutent in prostate cancer
28 September 2010
OSI/Genentech gain additional indication from US FDA for Tarceva as maintenance therapy for advanced NSCLC
19 April 2010
Switzerland’s Roche eyes up China’s potential
2 March 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Idera gets $4.3 million clinical milestone under its cancer drug deal with Merck KGaA
20 January 2010
FDA delays approval of OSI/Genentech/Roche’s Tarceva for advanced non-small cell lung cancer
18 January 2010
Pfizer drops figitumumab in NSCLC on disappointing Ph III; FDA delays Prevnar 13 and rejects Basilea/J&J’s ceftobiprole for cSSSI
4 January 2010
Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million
18 December 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
Stock Commentary - New York week to June 1, 2009
4 June 2009
Boehringer teams with DxS for EGFR assay
1 June 2009
Stock Commentary - New York week to May 18, 2009
21 May 2009
Tarceva improves PFS 41% in advanced NSCLC
18 May 2009
64% of BIBW 2992 patients see PR
18 May 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
Roche to trial Tarceva in EGFR lung cancer
28 April 2009
NexGen founder's patent improves chemo
30 March 2009
OSI Pharma sues Teva and Mylan over Tarceva patent
30 March 2009
OSI submits Tarceva in Europe and USA
30 March 2009
Mylan group sued over for first-to-file ANDAs
27 March 2009
Profit soars for OSI on income tax credit
2 March 2009
Teva files for generic of OSI's Tarceva
16 February 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
OSI shares jump 11.4% on Tarceva/Avastin benefit in NSCLC
9 February 2009
PharmaMar's Irvalec enters Ph I/II study with Tarceva
12 January 2009
NSCLC data could signal comeback for AZ's Iressa
1 December 2008
NICE recommends Roche's Tarceva as Taxotere alternative
1 December 2008
AZ has mixed bag of results from Ph III trials
24 November 2008
Tarceva extends PFS in advanced NSCLC
17 November 2008
UPDATE: Roche offers discount to UK NHS for Tarceva
13 October 2008
Tarceva plus Avastin miss Ph III endpoint
13 October 2008
Roche offers discount to NHS for Tarceva
13 October 2008
Idera reports first data from carcinoma trial
6 October 2008
Japan stock market week to July 28, 2008
4 August 2008
Roche's 1st-half net profit sees downturn
28 July 2008
Roche to lift stake in Chugai to 59.9%
2 June 2008
ArQule's 1st-qtr loss narrows to $13.9M
26 May 2008
Thai dispute over PReMA member for GPO board
5 May 2008
UK "No" for another cancer drug
5 May 2008
Generic firm accused of false promotion
28 April 2008
Abbott reports 35% rise in earnings
28 April 2008
Pfizer launches free Sutent program in Nepal
14 April 2008
OSI settle over Tarceva law suit
24 March 2008
Abbott and Genentech sign Tarceva assay deal
17 March 2008
AstraZeneca enrolls vandetanib Ph III trial in NSCLC
17 March 2008
Foreign groups try to stop Thailand CL climbdown
3 March 2008
Thailand Health Ministry change could mean fewer CLs
18 February 2008
India patent battle over Tarceva opens new CL front
21 January 2008
More NCEs added to Japan's NHI reimbursement list late December
14 January 2008
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
